semaglutide phase 3 ESSENCE trial: in metabolic dysfunction-associated steatohepatitis Three new phase 3 REIMAGINE

Heres how much you could save when using a generic semaglutide medication for weight loss.

Discover the U.S

Alabamas attorney general recently filed a lawsuit against a medical spa alleging that it administered unapproved versions of GLP-1 weight loss drugs to patients without informing them that the formulations were not authorized by the FDA

An observational study has uncovered a possible link between taking GLP-1s and increased risk of kidney, pancreas and gut issues.

Their lead candidate, ECC5004, is an oral GLP-1 agonist licensed to AstraZeneca for global development (excluding China), while Eccogene retains co-development and co-commercialization rights in China